135 related articles for article (PubMed ID: 36066182)
1. Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.
Ito T; Kinoshita K; Tomizawa M; Shinohara S; Nishii H; Matsushita M; Hattori K; Kohchi Y; Kohchi M; Hayase T; Watanabe F; Hasegawa K; Tanaka H; Kuramoto S; Takanashi K; Oikawa N
J Med Chem; 2022 Sep; 65(18):12427-12444. PubMed ID: 36066182
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
[TBL] [Abstract][Full Text] [Related]
3. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.
Wang Z; Ren J; Jia K; Zhao Y; Liang L; Cheng Z; Huang F; Zhao X; Cheng J; Song S; Sheng T; Wan W; Shu Q; Wu D; Zhang J; Lu T; Chen Y; Ran T; Lu S
Eur J Med Chem; 2022 Nov; 241():114601. PubMed ID: 35872544
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
5. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
[TBL] [Abstract][Full Text] [Related]
6. Discovery, Optimization, and Evaluation of Novel Pyridin-2(1
Xu Z; Peng X; Zhang R; Ji Y; You M; Wang D; Shen Y; Zheng M; Li C; Ai J; Liu H
J Med Chem; 2024 Jan; 67(2):1168-1183. PubMed ID: 38227770
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
El-Nassan HB; Al-Qadhi MA
Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
[TBL] [Abstract][Full Text] [Related]
8. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
[TBL] [Abstract][Full Text] [Related]
10. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review.
Panchal I; Tripathi RKP; Parmar K; Yadav MR
Curr Top Med Chem; 2024; 24(1):3-30. PubMed ID: 38058091
[TBL] [Abstract][Full Text] [Related]
13. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
[TBL] [Abstract][Full Text] [Related]
14. (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.
Choi HS; Rucker PV; Wang Z; Fan Y; Albaugh P; Chopiuk G; Gessier F; Sun F; Adrian F; Liu G; Hood T; Li N; Jia Y; Che J; McCormack S; Li A; Li J; Steffy A; Culazzo A; Tompkins C; Phung V; Kreusch A; Lu M; Hu B; Chaudhary A; Prashad M; Tuntland T; Liu B; Harris J; Seidel HM; Loren J; Molteni V
ACS Med Chem Lett; 2015 May; 6(5):562-7. PubMed ID: 26005534
[TBL] [Abstract][Full Text] [Related]
15. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
16. Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.
McCarthy C; Walker E
Expert Opin Ther Pat; 2014 Jul; 24(7):731-44. PubMed ID: 24809946
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
18. Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase.
Mei LC; Zhuo LS; Xu HC; Huang W; Hao GF; Yang GF
Eur J Med Chem; 2022 Jul; 237():114406. PubMed ID: 35486994
[TBL] [Abstract][Full Text] [Related]
19. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
20. Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo.
Wu T; Qin Q; Lv R; Liu N; Yin W; Hao C; Sun Y; Zhang C; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Aug; 238():114451. PubMed ID: 35617855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]